|
Categories
Pharmaceutical Company
Pharmaceutical Sales
Pharmaceutical
Distributor
Pharmaceutical
Preparation
Pharmaceutical
Jobs
Pharmaceutical
Industry
Pharmaceutical
Drug
Pharmaceutical
Sales Jobs
Pharmaceutical
Product
Pharmaceutical
News
Pharmaceutical
Research
Pharmaceutical
Manufacturer
Pharmaceutical Sales
Rep
Pharmaceutical
Sales Resume
Pharmaceutical
Online
Pharmaceutical
Marketing
Pharmaceutical
Dictionary
Pharmaceutical
Recruiter
Pharmaceutical
Supply
Pharmaceutical
Technology
Pharmaceutical
Advertising
Pharmaceutical
Schools
Companies
Pfizer Pharmaceutical
Wyeth Pharmaceutical
Watson Pharmaceutical
Merck Pharmaceutical
Roche Pharmaceutical
King Pharmaceutical
Teva Pharmaceutical
Aventis
Pharmaceutical
Novartis
Pharmaceutical
Forest
Pharmaceutical
Tap
Pharmaceutical
Shire
Pharmaceutical
Mayne
Pharmaceutical
Millennium
Pharmaceutical
Lilly
Pharmaceutical
Mylan
Pharmaceutical
Kos
Pharmaceutical
Takeda
Pharmaceutical
Endo
Pharmaceutical
Janssen
Pharmaceutical
Barr
Pharmaceutical
Abbott
Pharmaceutical
Reliant
Pharmaceutical
Solvay
Pharmaceutical
Amylin
Pharmaceutical
Vertex
Pharmaceutical
Osi
Pharmaceutical
Bayer
Pharmaceutical
Voyager
Pharmaceutical
Mcneil
Pharmaceutical
Boehringer
Ingelheim
Astra
Zeneca Pharmaceutical
Glaxosmithkline
Pharmaceutical
Novo Nordisk
Pharmaceutical
3m
Pharmaceutical
Eli
Lilly Pharmaceutical
Elan Pharmaceutical
Ivax
Pharmaceutical
Search engines:
Google
Lycos
AltaVista
Yahoo
Mirago
Ask
Teoma
Excite |
|
|
|
Elan Pharmaceutical
 Elan Pharmaceutical
Elan Corporation, plc is a
neuroscience-based biotechnology company that is focused on discovering,
developing, manufacturing and marketing advanced therapies in neurology,
autoimmune diseases, and severe pain.
On November 23, 2004, the U.S.
Food and Drug Administration approved TYSABRI® (natalizumab), formerly
referred to as Antegren, as treatment for relapsing forms of multiple sclerosis
(MS) to reduce the frequency of clinical relapses. On February 28, 2005, Biogen
Idec and Elan announced a voluntary suspension in the marketing of TYSABRI, a
multiple sclerosis (MS) therapy. The companies have also suspended natalizumab
dosing in natalizumab clinical trials for MS, Crohn’s disease and
rheumatoid arthritis.
On December 28, 2004, the U.S. Food and Drug
Administration (FDA) approved PRIALT® (ziconotide intrathecal infusion) for
the management of severe chronic pain in patients for whom intrathecal (IT)
therapy is warranted, and who are intolerant of or refractory to other
treatment, such as systemic analgesics, adjunctive therapies or IT morphine.
PRIALT is approved for use only in the Medtronic SynchroMed® EL,
SynchroMed® II Infusion System and CADD-Micro® ambulatory infusion
pump.
On February 22, 2005, the European Commission granted Elan
marketing approval for PRIALT™ (ziconotide) for the treatment of severe,
chronic pain in patients who require intrathecal (IT) analgesia.
Elan's
focus on improving the health of patients suffering from chronic and
debilitating conditions is exemplified by its breakthrough research program in
Alzheimer's disease, where it has developed three novel therapeutic
approaches:
Immunotherapy - In collaboration with Wyeth, this
approach targets the clearance of beta-amyloid, the peptide responsible for the
build-up of amyloid plaques in the brain
Beta secretase inhibitors -
Targets a distinct enzyme associated with the production of beta-amyloid
Gamma secretase inhibitors - Targets a distinct enzyme associated
with the production of beta-amyloid
In neurology, Elan is focused on
building upon its breakthrough research and extensive experience in the area of
neuropathology-based disorders. In addition to Alzheimer’s disease, Elan
is also studying other neurodegenerative diseases, such as Parkinson's disease.
In autoimmune diseases, Elan’s primary emphasis is studying and developing
ways to provide disease-modifying therapies for a wide range of diseases. In
severe pain, Elan’s research efforts focus on inflammatory and neuropathic
pain.
Elan Research & Development
Elan’s
discovery research efforts are centered on bringing science and innovation to
patients in its core therapeutic focus areas of neurology, autoimmune diseases
and severe pain.
In neurology, Elan is focused on building upon its
breakthrough research and extensive experience in the area of
neuropathology-related disorders such as Alzheimer’s disease, where the
company’s efforts include programs focused on small molecule inhibitors of
beta secretase and gamma secretase, enzymes whose actions are thought to affect
the accumulation of the amyloid plaques found in the brains of patients with
Alzheimer’s disease. Elan is also studying other neurodegenerative
diseases, such as Parkinson's disease.
In autoimmune diseases,
Elan’s primary emphasis is studying cell trafficking to discover ways to
provide disease-modifying therapies for autoimmune diseases such as rheumatoid
arthritis, multiple sclerosis and inflammatory bowel disease; and in severe
pain, research efforts focus on inflammatory and neuropathic
pain.
Elan - further information
www.elan.com
|
|
|
|
|
